Almitas Capital LLC Design Therapeutics, Inc. Transaction History
Almitas Capital LLC
- $212 Million
- Q2 2025
A detailed history of Almitas Capital LLC transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Almitas Capital LLC holds 1,530,435 shares of DSGN stock, worth $7.62 Million. This represents 2.43% of its overall portfolio holdings.
Number of Shares
1,530,435
Previous 1,452,896
5.34%
Holding current value
$7.62 Million
Previous $5.61 Million
8.04%
% of portfolio
2.43%
Previous 3.17%
Shares
5 transactions
Others Institutions Holding DSGN
# of Institutions
96Shares Held
33.6MCall Options Held
13KPut Options Held
0-
Sr One Capital Management, LP6.53MShares$32.5 Million7.89% of portfolio
-
Logos Global Management LP San Francisco, CA4.22MShares$21 Million1.83% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$11.5 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.95MShares$9.73 Million0.35% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.81MShares$9 Million0.01% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $278M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...